Ottawa – The latest edition of the Patented Medicine Prices Review Board (PMPRB) CompassRx report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000. CompassRx is an annual report published under the National Prescription Drug Utilization Information System (NPDUIS) research initiative. CompassRx provides insight into the factors driving prescription …